347 related articles for article (PubMed ID: 18405764)
1. Commentary on tolterodine for men with benign prostatic hyperplasia and lower urinary tract symptoms.
O'Leary MP
J Urol; 2008 May; 179(5 Suppl):S86. PubMed ID: 18405764
[No Abstract] [Full Text] [Related]
2. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
[TBL] [Abstract][Full Text] [Related]
3. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia.
Kaplan SA; Walmsley K; Te AE
J Urol; 2005 Dec; 174(6):2273-5. discussion 2275-6. PubMed ID: 16280803
[TBL] [Abstract][Full Text] [Related]
4. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
[TBL] [Abstract][Full Text] [Related]
5. How many drugs for LUTS due to BPH are too many?
Andersson KE
J Urol; 2008 Sep; 180(3):811-2. PubMed ID: 18635235
[No Abstract] [Full Text] [Related]
6. [Tolterodine tartrate combined with alpha-receptor blocker for benign prostatic hyperplasia with detrusor overactivity].
Gan W; Zhang SF; Jia HT; Xie S; Luo MH; Li YF
Zhonghua Nan Ke Xue; 2011 Apr; 17(4):348-50. PubMed ID: 21548214
[TBL] [Abstract][Full Text] [Related]
7. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
Wein AJ
J Urol; 2005 Jun; 173(6):2056-7. PubMed ID: 15879827
[No Abstract] [Full Text] [Related]
8. Tolterodine for overactive bladder.
Med Lett Drugs Ther; 1998 Oct; 40(1038):101-2. PubMed ID: 9813595
[No Abstract] [Full Text] [Related]
9. The efficacy of additive tolterodine extended release for 1-year in older men with storage symptoms and clinical benign proastatic hyperplasia.
Chung SD; Chang HC; Chiu B; Liao CH; Kuo HC
Neurourol Urodyn; 2011 Apr; 30(4):568-71. PubMed ID: 21344494
[TBL] [Abstract][Full Text] [Related]
10. Tolterodine for the treatment of daytime incontinence in children.
Greenfield SP
J Urol; 2005 Apr; 173(4):1064. PubMed ID: 15758701
[No Abstract] [Full Text] [Related]
11. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
[TBL] [Abstract][Full Text] [Related]
12. Editorial comment on: Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
Speakman MJ
Eur Urol; 2009 Sep; 56(3):542-3. PubMed ID: 19070420
[No Abstract] [Full Text] [Related]
13. Editorial comment on: Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
Dmochowski R
Eur Urol; 2009 Sep; 56(3):542. PubMed ID: 19070419
[No Abstract] [Full Text] [Related]
14. Re: safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
Schaefer W
J Urol; 2006 Nov; 176(5):2311-2; author reply 2312-3. PubMed ID: 17070326
[No Abstract] [Full Text] [Related]
15. Treatment of men with lower urinary tract symptoms and overactive bladder.
Young JG; Subramonian K
JAMA; 2007 Mar; 297(11):1192-3; author reply 1193. PubMed ID: 17374809
[No Abstract] [Full Text] [Related]
16. [A meta-analysis documenting the optimal tolerance profile of tolterodine].
Rev Med Suisse; 2006 May; 2(65):1234. PubMed ID: 16767876
[No Abstract] [Full Text] [Related]
17. Treatment of men with lower urinary tract symptoms and overactive bladder.
Bell WA; Amarshi N
JAMA; 2007 Mar; 297(11):1192; author reply 1193. PubMed ID: 17374810
[No Abstract] [Full Text] [Related]
18. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder.
Athanasopoulos AA; Perimenis PS
BJU Int; 2005 May; 95(7):1117-8. PubMed ID: 15839945
[No Abstract] [Full Text] [Related]
19. [More quality of life again with tolterodine].
Praxis (Bern 1994); 2006 Oct; 95(42):1636. PubMed ID: 17111848
[No Abstract] [Full Text] [Related]
20. Re: predictors of successful first-line antimuscarinic monotherapy in men with enlarged prostate and predominant storage symptoms.
Kaplan SA
J Urol; 2014 Jan; 191(1):157-8. PubMed ID: 24331493
[No Abstract] [Full Text] [Related]
[Next] [New Search]
